Concerning osteoporosis, SERMs exhibit agonistic effects on estrogen receptors related to bone homeostasis while antagonizing those mediating proliferative effects in uterine and breast tissue [55]. Drugs of this class that have proven helpful in osteoporosis include raloxifene and basedoxifene. Here, ESR1 is linked to osteoporosis.